Advances, an ASTRO Journal
@Advances_ASTRO
Advances in Radiation Oncology is a peer reviewed, open access journal from the American Society for Radiation Oncology. @ASTRO_org #AdvancesRO
Can we safely & effectively add radiation to immunotherapy for patients with hepatocellular carcinoma (HCC) with portal vein thrombus (PVT)? @nithyamurthy09 & colleagues retrospectively report on 62 HCC with PVT patients treated with ☑️concurrent (within 6 weeks) immunotherapy…
Expanding the #radonc toolkit for ☢️necrosis (RN) tx after SRS for functional disorders In this case report, Boswellia serrata resolved RN in a pt w/ steroid-refractory RN after SRS (80 Gy) for OCD Should Boswellia be a 1st line tx for RN after SRS? advancesradonc.org/article/S2452-…
Great work!
Remarkable response to Boswellia after necrosis due to high dose brain SRS. In case you didn’t know I am a strong advocate for Boswellia we should all be using this!!! advancesradonc.org/article/S2452-…
We've all experienced that relentless 🔁meningioma that keeps coming back! In this teaching case👩🏫, a fourth recurrence of atypical meningioma was treated with HDR brachytherapy to 21 Gy in 1 fraction given challenges with re-RT (prior 20 Gy and 30 Gy 9 and 2 years prior,…
❗️Out now: tinyurl.com/ycxku7pr❗️ In this Ph II trial (n=26), addition of IO (before, during, after) to definitive chemo☢️for pts w/ LA p16+ OPCs (cT4/3, matted LN, cENE) had: 🔘 2yr PFS: 65% (vs 68% historic control) 🔘 G3+ acute dysphagia: 54% 🔘 Incomplete IO course: 68%…
A prior study showed that male ♂️academic #radoncs are 3x times more likely to treat genitourinary (GU) maligancies than their female ♀️counterparts, and ♀️ #radoncs are more than twice as likely to treat gynecologic (GYN) malignancies than ♂️. With that in mind, what do female…
❗️OUT NOW - Dosi predictors of toxicity on PROMETHEUS study ❗️ In ♂️ w/ HR Pca receiving ☢️(46/23 + 19-20/2 SBRT boost), G2+ GU tox assoc w/ 🔘 Prior TURP 🔘 Prostatic urethra length 🔘 Urethra PRV volume 🔘 Bladder D10cc and D15cc #pcsm #radonc - tinyurl.com/3efsntx5
Thrilled to share our impact factor is rising and the highest it’s been since inception! Special thanks to our editors, editorial staff, and most of all, our readership and contributors to the journal!!! #ASTRO
Teaching Case: What are the outcomes after SBRT for urothelial ca of a transplanted kidney? After 13 mo, ☢️(40/5) to transplanted kidney associated w: 🔘❌ early/late adverse events 🔘✅ local control 🔘✅ stable eGFR RT planning + constraints reviewed:…
❗️Out now in Advances❗️ Prospective outcomes after proton re☢️(median 44.6 Gy) for pts w/ recurrent gliomas: 🔘 mOS 11.2mo - 🔼 w/ oligo histology, >60 mo from prior ☢️ 🔘 Acute G3 toxicity 8% -🔼 w/ poor PS (ECOG 2-3) 🔘 Late G1☢️necrosis: 19% tinyurl.com/38zk4aun
We are accepting articles for this special call now!
📢Hear ye, hear ye!👂We want to see what 🫵you've been up in the benign disease space! Submit your latest work on Radiation Indications for Non-Malignant Conditions by November 3, 2025. Questions❔DM us! advancesradonc.org/pb-assets/Heal…
In NSCLC, how does length of esophagus receiving ☢️impact patient-reported dysphagia? -Every 0.5cm 🔼 in 60 Gy to partial esoph circumference > 🔼 patient-reported dysphagia by 9% -Every 0.5cm 🔼 in 60+ Gy to full esoph circumference > 🔼 patient-reported dysphagia by 11%
PSMA radioligand therapy (PSMA-RLT) has a 📈survival benefit in metastatic castration resistant prostate cancer. But can we do a better job of choosing who RLT can benefit most❓🤔 👀Check out this case series that uses TRAQinformIQ, an automated image analysis tool, to…
☢️for benign dx is a 🔥 topic in #radonc: RT (20-30 Gy) for orbital inflammatory dx (Graves, IgG4, etc) associated with: -🔽steroid use: complete (56%), partial (33%) taper -🔽 👁️symptoms: diplopia, ptosis - <5% late side effects (dry 👁️, opacity) tinyurl.com/4bfxazbf
Have questions about our call for benign disease manuscripts?! Message us!
📢Hear ye, hear ye!👂We want to see what 🫵you've been up in the benign disease space! Submit your latest work on Radiation Indications for Non-Malignant Conditions by November 3, 2025. Questions❔DM us! advancesradonc.org/pb-assets/Heal…
Just a reminder to get those RT for benign disease projects going!
📢Hear ye, hear ye!👂We want to see what 🫵you've been up in the benign disease space! Submit your latest work on Radiation Indications for Non-Malignant Conditions by November 3, 2025. Questions❔DM us! advancesradonc.org/pb-assets/Heal…
Want a comprehensive meta-analysis of 15 metastasis-directed therapy (MDT) trials? 🔖Bookmark this post! This analysis found that MDT ✅significantly improved progression-free survival for all ✅benefited non-mutated or EGFR-mutated 🫁NSCLC & 👨🦳prostate cancer the most (not…
This truly collaborative study embodies what we strive for at Advances in Radiation Oncology... innovation! Want to add the newest & best to your skin RT practice? ⁉️Ever heard of Rhenium-skin cancer therapy? It is a non-invasive, epidermal radionuclide treatment for…
